{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:40:30Z","timestamp":1792269630991,"version":"4.4.0"},"reference-count":23,"publisher":"Japan Neurosurgical Society","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.2176\/jns-nmc.2026-0112","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T22:10:27Z","timestamp":1786659027000},"page":"377-383","source":"Crossref","is-referenced-by-count":1,"title":["Severe Central Nervous System Fungal Infection Following Tirabrutinib Administration in a Patient with Refractory Primary Central Nervous System Lymphoma: A Case Report"],"prefix":"10.2176","volume":"13","author":[{"given":"Jiro","family":"AKIMOTO","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Kohsei Chuo General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"NAKAMURA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kohsei Chuo General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"FUKUHARA","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kohsei Chuo General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"971","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994; 81 (2): 188-95. doi.10.3171\/jns.1994.81.2.0188","DOI":"10.3171\/jns.1994.81.2.0188"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2) Morris PG, Correa DG, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013; 31 (31): 3971-3979. doi:10.1200\/JCO.2013.50.4910","DOI":"10.1200\/JCO.2013.50.4910"},{"key":"3","unstructured":"3) Central nervous system cancers, version 3. J Natl Compr Canc Netw. 2025, NCCN Clinical Practice Guidelines in Oncology: 2025."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ferreri AJM, Illerhaus G, Doorduijin JK, et al. Primary central nervous system lymphomas: EHA-ESMO clinical practice guideline for diagnosis, treatment and follow up. Ann Oncol. 2024; 35 (6): 491-507. doi: 10.1016\/j.amnonc.2013.11.010","DOI":"10.1016\/j.annonc.2023.11.010"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5) Narita Y, Nagane M, Mishima K, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton&apos;s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neurol Oncol 2021; 23 (1): 122-33. doi: 10.1093\/neuonc\/noaa145","DOI":"10.1093\/neuonc\/noaa145"},{"key":"6","unstructured":"6) Nagane M. Practical guidelines for Neuro-Oncology Adult Edition 2024. The Japan Society for Neuro-Oncology; Kanehara Shuppan, 2024. Chapter 3, Primary Central Nervous System Lymphoma; p. 175-8."},{"key":"7","doi-asserted-by":"publisher","unstructured":"7) Arakawa Y, Narita Y, Nagane M, et al. Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I\/II study of tirabrutinib. Neuro-Oncol Adv 2023; 5 (1): vdad109. doi: 10.1093\/noajnl\/vdad109.","DOI":"10.1093\/noajnl\/vdad109"},{"key":"8","unstructured":"8) ONO MEDICAL NAVI. https:\/\/www.ononavi1717.jp\/system\/files\/2026-02\/side_effect_VLX_indication_0.pdf"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Arthurs B, Wunderle K, Hsu M, et al. Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia. Respir Med Case Rep. 2017; 21: 27-29. doi:10.1016\/j-rmcr.2017.03.011","DOI":"10.1016\/j.rmcr.2017.03.011"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10) Kreiniz N, Bejar J, Polliack A, et al. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematol Oncol 2018: 36 (1); 349-54. DOI:10.1002\/hon.2387.","DOI":"10.1002\/hon.2387"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Beresford R, Dolot V, Foo H. Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia. Med Mycol Case Rep. 2019; 24: 27-9. doi:10\/1016\/j.mmcr.2019.02.005.","DOI":"10.1016\/j.mmcr.2019.02.005"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Nyga R, Delette C, Mabille C, et al. Ibrutinib related cerebral aspergillosis successful treated with isavuconazole: a case report. Leuk Lymphoma. 2020; 61 (7): 1760-2. doi:10.1080\/10428194.2020\/1728749","DOI":"10.1080\/10428194.2020.1728749"},{"key":"13","unstructured":"13) Dunbar A, Joose ME, de Bore F, at al. Invasive fungal infections in patient with treated with Burton&apos;s tyrosine kinase inhibitors. Neth J Med. 2020; 78 (5): 294-296."},{"key":"14","doi-asserted-by":"publisher","unstructured":"14) Alkharabsheh O, Alsayed A, Morlote DM, et al. Cerebral invasive aspergillosis in a case of chronic lymphocytic leukemia with Bruton tyrosine kinase inhibitor. Curr Oncol. 2021; 28: 837-41. doi:10.3390\/curroncol28010081","DOI":"10.3390\/curroncol28010081"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15) Kitamura W, Kuyama S. Paranasal sinus aspergillosis in a patient treated with tirabrutinib. Int J Hematol. 2022; 116: 645-6. doi:10.1007\/s12185-022-03460-3","DOI":"10.1007\/s12185-022-03460-3"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16) Walsh M, Xu A, Ballas Z, at al. Disseminated fungal infection in a patient receiving zanubrutinib. Clin Case Rep. 2023; 11: e7564. doi:10.1002\/ccr3.7564","DOI":"10.1002\/ccr3.7564"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17) Blaize M, Thizy G, Boissonnas A, et al. Invasive aspergillosis with impaired neutrophil response against Aspergillus fumigatus in patient treated with acalabrutinib-findings from three cases. Int J Infect Dis. 2024;142: 107000. doi:10.1016\/j.ijid.2024.107000","DOI":"10.1016\/j.ijid.2024.107000"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18) Gilbert C, Blaize M, Fekkar A. Fungal infection in patient treated with Bruton tyrosine kinase inhibitor \u2013 from epidemiology to clinical outcome: a systematic review. Clin Microbiol Infect. 2025; 31 (5): 731-9. doi:10.1016\/j.cmi.2024.12.032.","DOI":"10.1016\/j.cmi.2024.12.032"},{"key":"19","unstructured":"19) Moreal C, Angelini J, Venturini S, et al. Management of invasive fungal infection: clinical strategies in Critical care from a multidisciplinary consensus. New Microbiol. 2025; 48: 211-4."},{"key":"20","doi-asserted-by":"publisher","unstructured":"20) Vargas-Blanco DA, Hepworth OW, et al. BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-\u03b1. JCI Insight 2024: 9 (12); e176162. doi: 10.1172\/jci.insight.176162","DOI":"10.1172\/jci.insight.176162"},{"key":"#cr-split#-21.1","doi-asserted-by":"crossref","unstructured":"21) Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma. Cancer Cell 2017: 31 (6)","DOI":"10.1016\/j.ccell.2017.04.012"},{"key":"#cr-split#-21.2","doi-asserted-by":"crossref","unstructured":"833-843. E5. Doi: 10.1016\/j.ccell. 2017.04.012.","DOI":"10.1088\/1475-7516\/2017\/04\/012"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22) Keany J, Gasser J, Gillet G, et al. Inhibition of Bruton&apos;s tyrosine kinase modulates microglial phagocytosis: therapeutic implications for Alzheimer&apos;s disease. J Neuroimmune Pharmacol. 2019; 14 (3): 448-461. doi:10.1007\/s11481-019-09839-0","DOI":"10.1007\/s11481-019-09839-0"}],"container-title":["NMC Case Report Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/13\/0\/13_2026-0112\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:23:05Z","timestamp":1786771385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/nmccrj\/13\/0\/13_2026-0112\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12,31]]},"references-count":23,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2176\/jns-nmc.2026-0112","relation":{},"ISSN":["2188-4226"],"issn-type":[{"value":"2188-4226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,12,31]]},"article-number":"2026-0112"}}